Thermo Fisher ScientificvsTrevi Therapeutics

TMO and TRVI stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$686.79

Value $255B

-0.66%
TMO's page

TRVI

Trevi Therapeutics, Inc.

$13.51

Value $1.9B

+1.66%
TRVI's page

Thermo Fisher Scientific (TMO) has a market value of $255B and Trevi Therapeutics (TRVI) $1.9B. Over the last year, with dividends, TMO moved +19.1% and TRVI +18.8%. Dividend yield: TMO 0.27%, TRVI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TMO$255B

    TRVI$1.9B

    TMO is 132 times TRVI

  • Revenue, 12 months

    TMO$47.4B

    TRVI–

  • Net income, 12 months

    TMO$7.1B

    TRVI-$61M

  • Operating margin

    TMO17.9%

    TRVI–

  • ROIC

    TMO8.2%

    TRVI-21.3%

    29.5 points apart

  • P/E

    TMO36.1

    TRVI–

  • Dividend yield

    TMO0.3%

    TRVI0.0%

    0.3 points apart

  • 5-year return

    TMO+8.6%

    TRVI+1,174.5%

    1,165.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TMO+8.6%

TRVI+1,175.0%

0100020222023202420252026
Returns by period
PeriodTMOWith dividendsTRVIWith dividends
1 year since November 14, 2025+19.1%Price +18.7%+18.8%Price +18.8%
3 years since November 17, 2023+48.7%+14.1% a yearPrice +47.2%+871.9%+113.4% a yearPrice +871.9%
5 years since November 16, 2021+8.6%+1.7% a yearPrice +7.1%+1,174.5%+66.4% a yearPrice +1,174.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TMOThermo Fisher ScientificTRVITrevi Therapeutics

Valuation

TMOTRVI
Valuation
Price$686.79$13.51
Market value$255B$1.9B
Enterprise value (EV)$290B$1.6B
P/E36.1–
P/E, 5-year median32.7–
P/B4.76.4
EV/EBIT34.3–
Free cash flow yield3.0%–

Results and growth

TMOTRVI
Results and growth
Revenue, 12 months$47.4B–
Net income, 12 months$7.1B-$61M
Free cash flow, 12 months$7.6B-$62M
Earnings per share, 12 months$18.96-$0.39
Revenue growth, year on year3.9%–
Revenue growth a year, past+6.7%over 5 years–
EPS growth a year, past+2.1%over 5 years–

Margins and returns on capital

TMOTRVI
Margins and returns on capital
Gross margin––
Operating margin17.9%–
Net margin14.9%–
ROIC8.2%-21.3%
ROE13.4%-26.0%

Balance sheet

TMOTRVI
Balance sheet
Cash$6.1B$299M
Total debt$41.4B$527.0K
Net debt / EBITDA3.7–
Interest cover5.5×–

Dividends and buybacks

TMOTRVI
Dividends and buybacks
Dividend yield0.3%–
Dividend per share, 12 months$1.84–
Dividend growth a year, past+14.3%over 5 years–
Buyback yield1.2%–
Shareholder yield1.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TMO or TRVI

Didn't find what you were looking for?

Ask us
Which is bigger, Thermo Fisher Scientific or Trevi Therapeutics?

By market value, Thermo Fisher Scientific ($255B) is about 132.5 times Trevi Therapeutics ($1.9B), at today's prices.

How did TMO and TRVI stock do over the last 5 years?

Since November 16, 2021, TMO's price moved +7.1% and TRVI's +1,174.5%. With dividends: TMO +8.6% (+1.7% a year), TRVI +1,174.5% (+66.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, TMO or TRVI?

The dividend yield at today's price is 0.27% for Thermo Fisher Scientific and none for Trevi Therapeutics. Over the last twelve months they paid $1.84 and – per share.

Which is the better investment, Thermo Fisher Scientific or Trevi Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.